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Objective: Vulnerability profiling, an alternative to deterministic risk assessment, offers 
  clinicians a more intuitive but empirically-grounded assessment of patient risk. This study 
aimed to determine whether a heuristic profile of high vulnerability is an independent predictor 
of uncontrolled hypertension.
Methods: Secondary analysis of prospective observational study data on 2999 hypertensive 
patients treated with valsartan. Predictive validity of vulnerability profiling for first-line, second-
line, and first-or-second-line antihypertensive treatment was inferred from 1) logistic regression 
models with adequate statistical fit, 2) statistically significant odds ratios for uncontrolled BP 
for the high-vulnerability cluster exceeding 1.00, and 3) correct classification rates for patients’ 
BP control status.
Results: All models of uncontrolled BP were significant (P , 0.001); all odds ratios for the 
high-vulnerability cluster were greater than 1.00 and significant (P , 0.001). Correct classifica-
tion rates for the highly-vulnerability cluster on uncontrolled BP after first-line, second-line, or 
either treatment were 91.1%, 61.2%, and 93.5% for systolic BP; 74.5%, 65.8%, and 76.7% for 
diastolic BP; and 92.8%, 65.3%, and 94.6% for combined systolic and diastolic BP.
Conclusion: The heuristic profile of “later, lazier, and unluckier” is an intuitive and valid tool 
to help identify patients at greater risk for poor BP control seen in general practice.
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Introduction
Although different formal algorithms to determine cardiovascular outcomes are 
  available (eg, Framingham risk score1 and SCORE project2), these tools are seldom 
used in primary care. Because of the required data collection, calculations, and time 
demands, as well as the deterministic nature of the results, using such algorithms rarely 
fits into the clinical flow of primary care encounters. The implicit prescriptive nature 
of these algorithms and that they provide a probabilistic assessment of comparable 
patients may further limit their utility in planning individual patient care. Moreover, 
deterministic systems can be criticized for discounting clinicians’ expertise in evalu-
ating patients and assessing risk. Thus, clinically-intuitive methods for identifying 
patients at greater risk are important, particularly in control of hypertension, in which 
blood pressure (BP)   targets are seldom reached3–6 and patients are at high-risk for 
target organ damage.7,8International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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We recently reported on determinants of BP outcomes 
and control after 90 days of second-line treatment with the 
angiotensin II receptor blocker valsartan.9 The PREVIEW 
study was an observational trial involving 3194 patients 
in whom first-line treatment failed or was not tolerated. 
We used hierarchical cluster analysis to identify sub-cohorts 
of patients with differential vulnerability to uncontrolled 
hypertension. Cluster analysis, a subclass of data-mining,10 
was used to discover latent patterns of subject similarity 
based on factors identified from the literature and clinical 
experience.11,12 We identified two clusters of patients with 
differential profiles of vulnerability to poor antihypertensive 
treatment outcomes.
As shown in Table 1, the highly-vulnerable cluster (HVC) 
of patients (n = 1063 or 35.4%) differed from the   remaining 
  vulnerable cluster (VC) of patients by: a) having been diagnosed 
relatively late and with more severe hypertension, b) weigh-
ing and drinking more, and exercising less, c) presenting with 
greater general, cardiovascular, and renal/endocrine risk and 
more comorbid cardiovascular disease, d) having a family 
history of premature cardiovascular   disease, and e) having a 
poor treatment response. Clinically, HVC patients had a higher 
propensity to be (only with   helpful clinical mnemonics in mind, 
and without any derogatory intent) “later, lazier, and unluckier.” 
In the PREVIEW study, the vulnerability clusters were deter-
minants of both BP   values and BP control as defined by the 
JNC-7/ESH-ESC13,14 guidelines (140/90 mmHg; for diabetics: 
130/80 mmHg) in multivariate models.9
These initial aggregate findings indicate that being a 
HVC patient is predictive of BP outcomes in multivariate 
models that include other determinants. However, in order 
to be able to recommend the HVC profile as a means of 
identifying patients who may not respond to antihyper-
tensive treatment, the profile must be further validated. 
This requires determining whether being a HVC patient 
is by and of itself a predictor of uncontrolled systolic BP 
(SBP), diastolic BP (DBP), and combined SBP/DBP – in 
the absence of other determinants. Further, the original 
analysis was limited to second-line treatment. It is also 
important to examine whether the HVC profile is predictive 
of uncontrolled BP after first-line treatment. These addi-
tional statistical analyses, which we report on in this present 
paper, are essential to determining the validity of the HVC 
profile as a predictor of poor response to antihypertensive 
treatment. Thus we examined the extent to which the HVC 
profile is an independent predictor of uncontrolled BP after 
first-line treatment (at physicians’ clinical discretion), after 
second-line treatment with valsartan, and after either first- or 
second-line treatment.
Methods
Procedures
Procedures for sampling, variables and measurements, data 
collection and management, statistical analysis, and manage-
ment of confounding variables are described in detail in the 
referent article.9
Table 1 Profiling of patients’ vulnerability to uncontrolled hypertension
Vulnerable patients   
(n = 1936)
Highly-vulnerable patients   
(n = 1063)
Mean (±SD) Mean (±SD) P-value
SBP when diagnosed 159.49 (±9.33) 182.13 (±14.20) ,0.001
DBP when diagnosed 94.07 (±6.90) 104.12 (±11.38) ,0.001
General riska 2.4060 (±1.54)  2.6058 (±1.55)  0.001
Cardiovascular riskb 0.6410 (±1.12) 0.7846 (±1.26) 0.002
Renal/endocrine riskc 0.1865 (±.061) 0.2389 (±.067) 0.038
% (95% CI) % (95% CI) P-value
Left ventricular hypertrophy 11.4% (10.3–12.5) 16.8% (15.6–18.0) ,0.001
Excessive alcohol use 16.0% (14.9–17.1) 18.9% (17.6–20.2) 0.023
Lack of exercise 55.8% (54.2–57.4) 61.1% (59.5–62.7) 0.005
Obesity 42.5% (40.9–44.1) 48.4% (46.7–50.1) 0.001
Family history of early cardiovascular disease 16.6% (15.4–17.8) 19.5% (18.2–20.8) 0.027
SBP controlled at start of treatment 10.4% (9.4–11.4) 6.1% (5.3–6.9) ,0.001
DBP controlled at start of treatment 27.9% (26.4–29.4) 21.3% (19.9–22.7) ,0.001
Notes: Data adapted from Van der niepen et al.9 aComposite score of occurrence of hypercholesterolemia, diabetes mellitus, smoking, excess alcohol use, lack of regular 
physical exercise, obesity, advanced retinopathy; bComposite score of occurrence of myocardial infarction, angina, coronary revascularization, left ventricular hypertrophy, 
ischemic and or hemorrhagic cerebrovascular accident, transient ischemic attacks, intermittent claudication, peripheral bypass or stent, and amputation; cComposite score of 
occurrence of microalbuminuria, renal impairment (serum creatinine .1.5 mg/dL), diabetic nephropathy, and proteinuria; (hemorrhages, exudates, papilloedema), C-reactive 
protein $1 mg/dL, and family history of premature cardiovascular disease (at age ,55 for men, ,65 for women).
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
165
Profile of high vulnerability to uncontrolled blood pressure
Modeling
Logistic regression modelling15 was used to model uncon-
trolled SBP, DBP, and SBP/DBP at 90 days. In this analysis, it 
was assumed that predictive validity could be inferred if four 
conditions were met. First, statistically significant logistic 
regression models could be fit using vulnerability profiles 
to predict uncontrolled BP. Second, odds ratios (ORs) for 
uncontrolled BP as a function of being highly vulnerable 
exceed 1.00, and the associated 95% confidence intervals 
(CIs) do not cross 1.00. Third, each model is sufficiently 
sensitive to correctly classify patients’ BP control status as 
indicated by the correct classification rate (CCR). Fourth, 
given the availability of data on initial BP control, and BP 
control after valsartan treatment, the first three conditions 
are met for first-line, second-line, and first-or-second-line 
antihypertensive treatment.
Results
Table 2 summarizes the logistic regressions for uncontrolled 
SBP, DBP, and combined SBP/DBP for HVC patients. All 
models were significant at P , 0.001. All ORs for HVC were 
statistically greater than 1.00 and none had 95% CIs crossing 
1.00 (all P , 0.001). CCRs for uncontrolled BP after first-, 
second-, or either treatment were 91.1%, 61.2%, and 93.5% 
for SBP; 74.5%, 65.8%, and 76.7% for DBP; and 92.8%, 
65.3%, and 94.6% for combined SBP/DBP.
Discussion
We accurately identified patients who had been diagnosed 
relatively late and with more severe hypertension (later); those 
weighing more, drinking more, and exercising less (lazier); 
and those who present with greater general, cardiovascular, 
and renal/endocrine risk and have a family history of 
premature cardiovascular disease (unluckier) as being highly-
vulnerable to poor BP control. Again, the profile’s labelling 
is only with clinical mnemonics in mind and without any 
derogatory intent.
Being a highly-vulnerable patient was significantly asso-
ciated with uncontrolled BP after first-line antihypertensive 
therapy with excellent predictive power. Thus, if patients 
presenting in the clinic fit the general profile of “later, lazier, 
and unluckier”, this should serve as a strong warning signal to 
clinicians that this subgroup of patients is much less likely to 
meet BP targets after first-line therapy, leaving them more prone 
to end-organ damage and requiring transition to second-line 
treatment. Likewise, this general profile was helpful in identi-
fying patients who were less likely to achieve BP control after 
either first- or second-line treatment, with minimally higher 
predictive validity compared to first-line therapy alone.
Many patients with hypertension are started on mono-
therapy and often require two or more antihypertensive agents 
in combination.13,14 Being a HVC patient increased the odds 
of having uncontrolled BP after second-line treatment, but 
with somewhat less predictive power. This may be due to the 
fact that second-line agents are started on patients who may 
be resistant to antihypertensive treatment, or patients in whom 
other factors, such as comorbid conditions or poor adherence, 
have not been identified and/or sufficiently addressed. This 
may be due to the fact that by switching from one antihy-
pertensive drug (first-line) to another (second-line) involved 
a change in antihypertensive class. In Belgium, thiazide 
diuretics are often prescribed as first-line antihypertensive 
drugs; thus, changing to valsartan often involved a switch 
from an antivolume to an antiresistance drug.16 Fitting the 
general profile of “later, lazier, and unluckier”, however, 
should serve as a caution for clinicians that this subgroup of 
patients is also less likely to meet BP targets after second-
line treatment.
Conclusion
With this additional evidence of the predictive validity of 
vulnerability profiling on BP control, clinicians have a more 
intuitive but empirically-grounded assessment of patient risk. 
The general profile of “later, lazier, unluckier” is helpful in 
identifying patients at greater risk for poor BP control.
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Table 2 Logistic regression results of uncontrolled blood pressure 
at follow-up as a function of membership in the high-vulnerability 
cluster
OR 95% CI CCR
After first-line treatment
  uncontrolled SBP 1.789 1.338 to 2.391 91.1%
  uncontrolled DBP 1.443 1.200 to 1.711 74.5%
  uncontrolled SBP/DBP 1.550 1.137 to 2.115 92.8%
After second-line treatment with valsartan
  uncontrolled SBP 1.562 1.331 to 1.833 61.2%
  uncontrolled DBP 1.534 1.309 to 1.797 65.8%
  uncontrolled SBP/DBP 1.717 1.455 to 2.028 65.3%
After either first- or second-line treatment
  uncontrolled SBP 2.071 1.459 to 2.940 93.5%
  uncontrolled DBP 1.553 1.290 to 1.869 76.7%
  uncontrolled SBP/DBP 1.898 1.340 to 2.761 94.6%
Abbreviations:  CCR,  correct  classification  rate;  CI,  confidence  interval;  DBP, 
diastolic blood pressure; OR, odds ratio; SBP, systolic blood pressure.International Journal of General Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-general-medicine-journal
The International Journal of General Medicine is an international, 
peer-reviewed open-access journal that focuses on general and internal 
medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-
ment protocols. The journal is characterized by the rapid reporting of 
reviews, original research and clinical studies across all disease areas. 
A key focus is the elucidation of disease processes and management 
protocols resulting in improved outcomes for the patient.The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
166
Abraham et al
from Novartis Pharma. Drs Vancayzeele and Brié and 
Ms Hermans are employees of Novartis Pharma.
References
1.  D’Agostino RBS, Grundy S, Sullivan LM, Wilson P. Validation of 
the Framingham coronary heart disease prediction scores: results of a 
multiple ethnic groups investigation. JAMA. 2001;286:180–187.
2.  Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of 
fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 
2003;24:987–1003.
3.  Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of 
blood pressure in a hypertensive population. New Engl J Med. 1998;339: 
1957–1963.
4.  Fagard RH, Van den Enden M, Leeman M, Warling X. Survey on treat-
ment of hypertension and implementation of World Health Organization/
International Society of Hypertension risk stratification in primary care 
in Belgium. J Hypertens. 2002;20:1297–1302.
5.  Van der Niepen P, Giot C, van de Borne P. Prevalence of isolated uncon-
trolled systolic blood pressure among treated hypertensive patients in 
primary care in Belgium. Results of the I-inSYST survey. J Hypertens. 
2008;26:2057–2063.
6.  Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, aware-
ness, treatment, and control of hypertension among United States adults 
1999–2004. Hypertension. 2007;49:69–75.
7.  Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood 
pressure reduction: a quantitative overview updated until 2003 March 1. 
J Hypertens. 2003;21:1055–1076.
  8.  Kannel WB. Elevated systolic blood pressure as a cardiovascular risk 
factor. Am J Cardiol. 2000;85:251–255.
  9.  Van der Niepen P, Woestenburg A, Brié H, et al. Effectiveness vs efficacy 
of valsartan for treatment of hypertension: patient profiling and hier-
archical modeling of determinants and outcomes. Ann   Pharmacother. 
2009;43:849–861.
  10.  Tan PN, Steinbach M, Kumar V . Data Mining. Boston, MA: Addison-
Wesley; 2005.
  11.  Aldenderfer MS, Blashfield RK. Cluster Analysis. Thousand Oaks, CA: 
Sage; 1984.
  12.  Everitt BS, Landau B, Leese M. Cluster analysis. 2001. 4th ed.   
New York: Oxford University Press.
  13.  Chobanian AV , Bakris GL, Black HR, et al. The Seventh Report of the 
Joint National Committee on prevention, detection, evaluation, and 
treatment of high blood pressure: the JNC-7 report. J Am Med Assoc. 
2003;289:2560–2572.
  14.  Guidelines Committee. 2003 European Society of Hypertension – 
E  uropean Society of Cardiology guidelines for the management of 
arterial hypertension. J Hypertens. 2003;21:1011–1053.
  15.  Kleinbaum DG, Klein M. Logistic regression. 2005. 2nd ed. New York, 
NY: Springer-Verlag.
  16.  Laragh JH. Abstract, closing summary, and table of contents for 
  Laragh’s 25 lessons in pathophysiology and 12 clinical pearls for 
  treating hypertension. Am J Hypertens. 2001;14:1173–1174.